Skip to main content

Press Releases

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Date Title
Toggle Summary Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results
WESTLAKE VILLAGE, Calif. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the second quarter of 2017. “We are pleased to report the results of our second quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WESTLAKE VILLAGE, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the closing of the Company’s initial public offering of 4,983,333 shares of common stock at a public offering price of $15.00 per share, which includes the exercise in full by
Toggle Summary Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts.
Toggle Summary Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors
WESTLAKE VILLAGE, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products
Toggle Summary Sienna Biopharmaceuticals Announces $40 Million Series B Financing
Topical Biotech Innovation in Medical Dermatology and Aesthetics WESTLAKE VILLAGE, Calif.--( BUSINESS WIRE )-- Sienna Biopharmaceuticals, Inc. , a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by
Toggle Summary Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
Seasoned Executive Brings Experience from Medicis and Novan WESTLAKE VILLAGE, Calif. , March 24, 2017 /PRNewswire/ --  Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage medical dermatology and aesthetics company, today announced that Richard Peterson will join the company as
Toggle Summary Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
Appointment Marks Pyott's Return to Dermatology and Aesthetics WESTLAKE VILLAGE, Calif. , Feb. 28, 2017 /PRNewswire/ --  Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage medical dermatology and aesthetics company, is pleased to announce that David E.I.